Michael Hebeisen Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Switzerland
1 protocol

Nathalie Rufer Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Switzerland
1 protocol

Pedro Romero Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
3 protocols

Petra Baumgaertner Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
1 protocol

Daniel E. Speiser
  • Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
  • 1 Author merit


M.D in University of Zürich, Switzerland, 1982

Current position

Associate and Full Professor, respectively, University of Lausanne, Switzerland

Publications (selected)

  1. Robert-Tissot, C. and Speiser, D. E. (2016). Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies. Cancer Discov 6(1): 17-19.

  2. Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P. and Speiser, D. E. (2015). Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112(19): 6140-6145.

  3. Fuertes Marraco, S. A., Soneson, C., Cagnon, L., Gannon, P. O., Allard, M., Abed Maillard, S., Montandon, N., Rufer, N., Waldvogel, S., Delorenzi, M. and Speiser, D. E. (2015). Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile upon yellow fever vaccination. Sci Transl Med 7(282): 282ra248.

  4. Speiser, D. E., Utzschneider, D. T., Oberle, S. G., Munz, C., Romero, P. and Zehn, D. (2014). T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 14(11): 768-774.

  5. Utzschneider, D. T., Legat, A., Fuertes Marraco, S. A., Carrie, L., Luescher, I., Speiser, D. E. and Zehn, D. (2013). T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 14(6): 603-610.

  6. Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O., Zoete, V., Michielin, O., Muehlethaler, K., Speiser, D., Beckmann, J. S., Xenarios, I., Halazonetis, T. D., Jongeneel, C. V., Stevenson, B. J. and Antonarakis, S. E. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44(2): 133-139.

  7. Baitsch, L., Baumgaertner, P., Devevre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., Rufer, N. and Speiser, D. E. (2011). Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest 121(6): 2350-2360.

  8. Speiser, D. E., Lienard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A. M., Cerottini, J. C. and Romero, P. (2005). Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115(3): 739-746.

  9. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M. and Ohashi, P. S. (1997). Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186(5): 645-653.

  10. Speiser, D. E., Stubi, U. and Zinkernagel, R. M. (1992). Extrathymic positive selection of alpha beta T-cell precursors in nude mice. Nature 355(6356): 170-172.

  11. Speiser, D. E., Lees, R. K., Hengartner, H., Zinkernagel, R. M. and MacDonald, H. R. (1989). Positive and negative selection of T cell receptor V beta domains controlled by distinct cell populations in the thymus. J Exp Med 170(6): 2165-2170.

1 Protocol published
Chromium-51 (51Cr) Release Assay to Assess Human T Cells for Functional Avidity and Tumor Cell Recognition
Authors:  Petra Baumgaertner, Daniel E. Speiser, Pedro Romero, Nathalie Rufer and Michael Hebeisen, date: 08/20/2016, view: 2391, Q&A: 0
Cytotoxic CD8+ T cells are able to specifically recognize and kill target cells through specific interaction between their T cell receptors (TCRs) and small immunogenic peptides (antigens) presented by major histocompatibility complex ...